Medicine

Z. Tong, Yangang Xing, S. Jiang, X. Li, Mengming Michael Dong

2021Adverse Drug Reactions Journal

DOI: 10.3760/cma.j.cn114015-20210709-00772

tlooto Summary

The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower incancer patients, especially in patients with haematological malignancies, than in healthy individuals.

Abstract

Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals. Copyright © 2021 by the Chinese Medical Association.

Citation format

TONG, Z., et al. Coronavirus disease 2019 vaccination in cancer patients. Adverse Drug Reactions Journal, 2021, 23: 352–356.